# Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)

Study · id `cardio:ct-nct07687706` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07687706](<https://clinicaltrials.gov/study/NCT07687706>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07687706

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1524 participants.

## Technical summary

Registry record NCT07687706. Randomized; triple masking; primary purpose prevention. Start 2026-01-26 (actual); primary completion 2027-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 1524 participants (planned count; ClinicalTrials.gov record NCT07687706, source copy `cardio:ctgov-nct07687706-2026-07-08`, retrieved 2026-10-26)
- Started: 2026-01-26 (actual) (ClinicalTrials.gov record NCT07687706, source copy `cardio:ctgov-nct07687706-2026-07-08`, retrieved 2026-10-26)
- Primary completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT07687706, source copy `cardio:ctgov-nct07687706-2026-07-08`, retrieved 2026-10-26)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT07687706, source copy `cardio:ctgov-nct07687706-2026-07-08`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07687706, source copy `cardio:ctgov-nct07687706-2026-07-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07687706-2026-07-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)
- Acronym: TegoStroke
- Condition: Ischemic Stroke
- Condition: Ischemic Stroke, Acute
- Condition: Transient Ischemic Attack (TIA)
- Condition: Cerebrovascular Disease
- Condition: Gastrointestinal Complication
- Condition: Gastrointestinal Bleeding
- Intervention (Drug): Tegoprazan 50 mg
- Intervention (Drug): Placebo
- Lead sponsor: Hanyang University Guri Hospital
- Lead sponsor class: OTHER
- Collaborator: HK inno.N Corporation
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Transient ischemic attack (mini-stroke) (`cardio:transient-ischemic-attack`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as a collaborator: HK inno.N Corporation (`cardio:org-hk-inno-n-corporation`)

## Provenance

Content hash: 9d065b0b2eb756c5244a7366cfc86ac022b5d6fddab2e94d35705b6b0af41415
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
